Bulletin
Investor Alert

Adagio Therapeutics Inc.

NAS: ADGI

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Adagio Therapeutics Inc.

After Hours

 --Quotes are delayed by 20 min

May 20, 2022, 7:45 p.m.

ADGI
/zigman2/quotes/228559245/composite

$

2.96

Change

+0.01 +0.34%

Volume

Volume 16,198

Quotes are delayed by 20 min

/zigman2/quotes/228559245/composite

Previous close

$ 2.97

$ 2.95

Change

-0.02 -0.67%

Day low

Day high

$2.81

$3.12

Open

52 week low

52 week high

$2.46

$78.82

Open

Company Description

Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoc...

Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren? Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

Valuation

Price to Book Ratio

1.44

Enterprise Value to EBITDA

1.22

Efficiency

Liquidity

Current Ratio

9.94

Quick Ratio

9.94

Cash Ratio

9.53

Profitability

Return on Assets

-61.50

Return on Equity

-68.48

Return on Total Capital

-66.25

Capital Structure

Officers and Executives

Name Age Officer Since Title
Mr. David Hering 46 2021 Chief Operating Officer
Ms. Jane Pritchett V. Henderson 57 2020 Chief Financial Officer
Dr. Laura Walker 36 2020 Chief Scientific Officer
Dr. Rebecca L. Dabora 62 2020 Chief Technology & Manufacturing Officer
Dr. Elham Hershberger 53 2020 Chief Development Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
03/03/2022 Adimab LLC
1,158,089   0
08/10/2021 Adimab LLC
25,860,700   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2021 Mithril Capital Management LLC
9,244,580   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2021 Polaris Growth Management LLC
320,160   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2021 Polaris Growth Management LLC
4,755,460   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2021 Polaris Growth Management LLC
28,520   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2021 Polaris Growth Management LLC
19,540   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2021 Polaris Growth Management LLC
55,595   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2021 Polaris Growth Management LLC
2,852,425   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2021 Redmile Group LLC
1,920,960   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2021 Mithril Capital Management LLC
1,997,000   Acquisition at $17 per share. 33,949,000
08/10/2021 Polaris Growth Management LLC
177,500   Acquisition at $17 per share. 3,017,500
08/10/2021 Polaris Growth Management LLC
45,000   Acquisition at $17 per share. 765,000
08/10/2021 Polaris Growth Management LLC
2,678   Acquisition at $17 per share. 45,526
08/10/2021 Polaris Growth Management LLC
1,834   Acquisition at $17 per share. 31,178
08/10/2021 Polaris Growth Management LLC
5,219   Acquisition at $17 per share. 88,723
08/10/2021 Polaris Growth Management LLC
267,769   Acquisition at $17 per share. 4,552,073
08/10/2021 Redmile Group LLC
1,470,000   Acquisition at $17 per share. 24,990,000
/news/latest/company/us/adgi

MarketWatch News on ADGI

  1. Biotech Stocks Are Still Falling. The Near-Term Outlook Is Grim.

    10:21 a.m. May 2, 2022

    - Barron's Online

  4. Adagio Stock Spikes on New Data, but Its Omicron Problems Remain

    9:33 a.m. March 30, 2022

    - Barron's Online

  8. Adagio Therapeutics downgraded to underweight at Morgan Stanley

    11:45 a.m. Jan. 6, 2022

    - Tomi Kilgore

  9. Adagio Therapeutics downgraded to hold from buy at Stifel, price target slashed to $9 from $50

    10:25 a.m. Dec. 15, 2021

    - Tonya Garcia

  13. Adagio Therapeutics upgraded to overweight at Morgan Stanley

    10:30 a.m. Nov. 29, 2021

    - Tomi Kilgore

  15. Adagio Therapeutics started at buy with $57 stock price target at Stifel Nicolaus

    7:30 a.m. Aug. 31, 2021

    - Tomi Kilgore

  16. The IPO Market Is on Break. Adagio Is Friday's Only Deal.

    4:32 p.m. Aug. 6, 2021

    - Barron's Online

  19. Adagio Therapeutics sets IPO terms, to be valued at up to $1.8 bln

    6:38 a.m. Aug. 2, 2021

    - Tomi Kilgore

/news/nonmarketwatch/company/us/adgi

Other News on ADGI

  1. 10-Q: ADAGIO THERAPEUTICS, INC.

    8:04 a.m. May 13, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  3. Adagio's (ADGI) COVID-19 Antibody Meets Goals in Studies

    12:14 p.m. March 31, 2022

    - Zacks.com

  4. 10-K: ADAGIO THERAPEUTICS, INC.

    8:21 a.m. March 31, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  6. AKBA, TMC and ISIG among mid-day movers

    12:42 p.m. March 30, 2022

    - Seeking Alpha

  7. Why Adagio Therapeutics Stock Is Soaring Today

    10:50 a.m. March 30, 2022

    - Motley Fool

  8. ABVC, SNOA and TISI among pre market gainers

    8:29 a.m. March 30, 2022

    - Seeking Alpha

  9. These 2 Nasdaq Biotech Stocks Are Soaring Wednesday Morning

    8:24 a.m. March 30, 2022

    - Motley Fool

  11. 2 Net Current Asset Value Stocks to Consider

    4:32 p.m. March 23, 2022

    - GuruFocus.com

  12. Adagio's Round Trip

    2:01 p.m. March 2, 2022

    - Seeking Alpha

  13. Adagio Therapeutics names David Hering as interim CEO

    5:54 p.m. Feb. 23, 2022

    - Seeking Alpha

  15. Adagio falls after announcing resignation of CEO

    9:19 a.m. Feb. 22, 2022

    - Seeking Alpha

  19. GLSI, VCNX and ACY among mid-day movers

    1:40 p.m. Feb. 10, 2022

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Adagio Therapeutics, Inc.

1601 Trapelo Road

Suite 178

Waltham, Massachusetts 02451

Phone

1 7818190080

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

View SEC Filings

Revenue

N/A

Net Income

$-226.79M

Employees

103.00

Annual Report for ADGI

/news/pressrelease/company/us/adgi

Press Releases on ADGI

  10. Adagio Therapeutics Announces CEO Succession Plan

    8:33 p.m. Feb. 18, 2022

    - GlobeNewswire

  21. Loading more headlines...
Link to MarketWatch's Slice.